07:55 AM EST, 12/11/2024 (MT Newswires) -- Satellos Bioscience ( MSCLF ) (MSCL.TO on Wednesday said that the first participant with Duchenne muscular dystrophy (DMD) has been dosed in the phase 1b safety and pharmacokinetics trial in DMD patients.

The company expects to enroll up to 10 adult participants with genetically confirmed DMD in a 28-day, open-label, single dose cohort.

"The dosing of our first DMD participant is a major milestone in evaluating SAT-3247's potential benefit for DMD patients," said Frank Gleeson, Satellos Co-founder and CEO. "We are very pleased to have safely completed the full enrollment and dosing of all five cohorts in the single ascending dose study and the first two multiple ascending dose cohorts. This reinforces our view that SAT-3247 has potential to be a safe and tolerable, once-daily, oral treatment option for DMD patients."